Clinical trial
Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic…
NCT00397904 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00397904 |
|---|---|
| Title | Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin |
| Official title | Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Irinotecan and Cisplatin-Refractory Metastatic Esophageal and Gastric Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Biological, Drug, Other, Procedure |
| Interventions | cetuximab, cisplatin, irinotecan hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis, biopsy |
| Enrollment | 16 |
| Start date | Oct 1, 2006 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Nov 10, 2006 |
| Last update posted | Nov 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: